http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#Head http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#assertion http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#provenance http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#pubinfo http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#assertion http://purl.obolibrary.org/obo/DOID_14320 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_14320 http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01175 http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association http://www.w3.org/2000/01/rdf-schema#label escitalopram oxalate is a selective serotonin reuptake inhibitor ssri indicated for acute and maintenance treatment of major depressive disorder mdd in adults and adolescents aged 12 17 years 1 1 acute treatment of generalized anxiety disorder gad in adults 1 2 acute treatment of generalized anxiety disorder gad in adults 1 2 escitalopram tablets usp are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age see clinical studies 14 1 a major depressive episode dsm iv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least five of the following nine symptoms depressed mood loss of interest in usual activities significant change in weight and or appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration a suicide attempt or suicidal ideation escitalopram tablets usp are indicated for the acute treatment of generalized anxiety disorder gad in adults see clinical studies 14 2 generalized anxiety disorder dsm iv is characterized by excessive anxiety and worry apprehensive expectation that is persistent for at least 6 months and which the person finds difficult to control it must be associated with at least 3 of the following symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension and sleep disturbance http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01175 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#provenance http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#pubinfo http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#sig http://purl.org/nanopub/x/hasSignature PuCBfcb/k8hRBzRl59Z3br3bINbcQfvlh41b6woxKM8wl+2h1Tz7Dj4bbSkbg7Xdu7o0XbxbFENdgYBNFPKtdDOkJQ+lmurx3FRTn/8N9YxEIXn1aMy+btuuyyL4ti9EycYOEhA0WSgVB35KX+Pvxxvhpy7K6CsX1GB1IaDZUFM= http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 http://purl.org/dc/terms/created 2021-06-13T14:10:53.808+02:00 http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAio-E_K_Jf2_Wf4n_7e9rFdZOvE21NKpuX_CN9PF1ph8 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs